Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis

被引：6
|
作者：
Panchal, Shyam C. [1 ]
Ondo, William G. [1 ]
机构：
[1] Houston Methodist Neurol Inst, Dept Neurol, 6560 Fannin St,Scurlock Tower,Suite 802, Houston, TX 77030 USA
来源：
CURRENT PSYCHIATRY REPORTS | 2018年 / 20卷 / 01期
关键词：
Parkinson's disease; Psychosis; Hallucinations; Delusions; Pimavanserin; Antipsychotic; DRUG-INDUCED PSYCHOSIS; LEVODOPA-INDUCED PSYCHOSIS; VISUAL HALLUCINATIONS; DOUBLE-BLIND; RISK-FACTORS; OLANZAPINE TREATMENT; BEHAVIORAL SYMPTOMS; CLOZAPINE TREATMENT; POSITIVE SYMPTOMS; RATING-SCALE;
D O I：
10.1007/s11920-018-0869-z
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Purpose of Review We discuss features of Parkinson's disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. Recent Findings Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing. Summary PDP is a morbid complication of Parkinson's disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis
    Shyam C. Panchal
    William G. Ondo
    Current Psychiatry Reports, 2018, 20
  • [2] DELUSIONS AND HALLUCINATIONS CORRELATES IN PARKINSON'S DISEASE PSYCHOSIS
    Rothenberg, Kasia Gustaw
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2022, 30 (04): : S122 - S122
  • [3] Understanding the Burden and Management of Hallucinations and Delusions Associated With Parkinson's Disease Psychosis
    Kremens, Daniel E.
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22
  • [4] MORTALITY RISK ASSOCIATED WITH PIMAVANSERIN FOR HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
    Isaacson, S.
    Pagan, F.
    Truong, D.
    Abler, V.
    Pahwa, R.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 49 - 49
  • [5] HALLUCINATIONS AND DELUSIONS IN PATIENTS WITH PARKINSON'S DISEASE - EVALUATION BY THE PARKINSON PSYCHOSIS QUESTIONNAIRE
    Sawada, H.
    Oeda, T.
    Umemura, A.
    Tomita, S.
    Hayashi, R.
    Kohsaka, M.
    Nakano, H.
    Yamamoto, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 518 - 518
  • [6] Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions
    Isaacson, Stuart H.
    Citrome, Leslie
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (07) : 873 - 879
  • [7] Hallucinations and psychosis in Parkinson's disease
    Rabey, Jose Martin
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S105 - S110
  • [8] Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis
    Kulick, Catherine V.
    Montgomery, Kathryn M.
    Nirenberg, Melissa J.
    PARKINSONISM & RELATED DISORDERS, 2018, 54 : 40 - 45
  • [9] Cognitive correlates of hallucinations and delusions in Parkinson's disease
    Factor, Stewart A.
    Scullin, Michael K.
    Sollinger, Ann B.
    Land, Julia O.
    Wood-Siverio, Cathy
    Zanders, Lavezza
    Freeman, Alan
    Bliwise, Donald L.
    McDonald, William M.
    Goldstein, Felicia C.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 347 (1-2) : 316 - 321
  • [10] Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
    G. Fabbrini
    P. Barbanti
    C. Aurilia
    C. Pauletti
    G. L. Lenzi
    G. Meco
    Neurological Sciences, 2002, 23 : 41 - 43
12345